Loading
AbbVie Inc. Stock: price and insider trades · United States
AbbVie Inc.: what insiders have been doing
AbbVie Inc., classified in the Healthcare & Pharma sector, is a listed company based in North Chicago, United States, founded in 2012. Its insiders report their share dealings to SEC (Form 4). Over the twelve months to 18 October 2026, 35 filings were filed, from 21 insiders.
All open-market trades in the period are sales: 2 sales worth €8.1M, by 2 insiders, with no purchase on record. One trade stands out by size: a sale of €7.1M from Donoghoe Nicholas, disclosed on 18 August 2026, or 0.0017% of market capitalisation.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
For context, the typical company on the same exchange (median of 5,813 companies) published 19 filings over the same period, against 35 filings here. Looking back to 2016, when coverage begins, insiders filed no purchases and 30 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 61.16 bn USD and net income of 4.23 bn USD, with a dividend of 6.65 USD per share.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
361
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€52M
30 ops. · all time
Who traded when
BuySaleNicholas Donoghoe2 sales
Buckbee Kevin K1 sale
David Ryan Purdue1 sale
Perry C. Siatis1 sale
Richmond Timothy J.1 sale
Scott T. Reents1 sale
Analyst consensus: bullish or bearish?
Analysts rate AbbVie Inc. Buy (bullish), based on 28 analysts. Average price target: US$282.61.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 14,175 of 24,148 companies
46.4
score / 100
Value35
Quality58
FCF yld3.6%
Earn yld0.8%
EV/EBITDA32.2x
ROE·
Gross mgn70%
Net mgn6.9%
Debt/EBITDA3.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$283.48
Analyst consensus
28 analystsBuy
US$200.00Target US$282.61(-0%)US$328.00
Income statement
RevenueUS$61.2B
Gross profitUS$43B70% margin
EBITDAUS$17.6B29% margin
Net incomeUS$4.2B9.8% margin
Valuation
PER (trailing)80.1x
PER (forward)17.5x
Beta0.23
Balance sheet & cash
Market capUS$500.9B
Total debtUS$67.5B
Free Cash FlowUS$17.8B
Profitability & ownership
ROA10.5%
% insiders0.1%
% institutions77.3%
Last declaration on 18 August 2026
Declarations361 total
32,710 shares@ US$79.020.0005% mcap10.6% of flowCommon Stock, $0.01 par valueSEC:0001762951-26-000006:0
32,710 shares@ US$250.000.0017% mcap33.4% of flowCommon Stock, $0.01 par valueSEC:0001762951-26-000006:1
32,710 shares@ US$250.000.0017% mcap100.0% of flowCommonSEC144:0001950047-26-008158
1,118 shares0Common Stock, $0.01 par valueSEC:0001061632-26-000004:0
1,118 shares0Common Stock, $0.01 par valueSEC:0001171780-26-000010:0
1,118 shares0Common Stock, $0.01 par valueSEC:0001222890-26-000003:0
1,118 shares0Common Stock, $0.01 par valueSEC:0001223690-26-000004:0
1,118 shares0Common Stock, $0.01 par valueSEC:0001239126-26-000002:0
1,118 shares0Common Stock, $0.01 par valueSEC:0001355580-26-000002:0
1,118 shares0Common Stock, $0.01 par valueSEC:0001466338-26-000003:0
1,118 shares0Common Stock, $0.01 par valueSEC:0001563579-26-000002:0
1,118 shares0Common Stock, $0.01 par valueSEC:0001706126-26-000002:0
1,118 shares0Common Stock, $0.01 par valueSEC:0001916665-26-000002:0
1,118 shares0Common Stock, $0.01 par valueSEC:0001997505-26-000006:0
2,108 shares@ US$232.0820.8% of flowCommon Stock, $0.01 par valueSEC:0002057696-26-000010:0
1,594 shares@ US$232.08100.0% of flowCommon Stock, $0.01 par valueSEC:0002078592-26-000004:0
5,230 shares@ US$233.5652.7% of flowCommon Stock, $0.01 par valueSEC:0002057696-26-000008:0
12,874 shares@ US$232.0811.9% of flowCommon Stock, $0.01 par valueSEC:0001762951-26-000004:0
2,692 shares@ US$232.0826.5% of flowCommon Stock, $0.01 par valueSEC:0002057696-26-000004:0
14,850 shares@ US$232.0820.5% of flowCommon Stock, $0.01 par valueSEC:0001951400-26-000006:0
21,638 shares@ US$232.0834.0% of flowCommon Stock, $0.01 par valueSEC:0001937048-26-000004:0
23,812 shares@ US$232.0818.5% of flowCommon Stock, $0.01 par valueSEC:0001761675-26-000004:0
36,523 shares@ US$232.0823.7% of flowCommon Stock, $0.01 par valueSEC:0001699914-26-000004:0
8,037 shares@ US$232.0847.7% of flowCommon Stock, $0.01 par valueSEC:0002004979-26-000004:0
16,309 shares@ US$232.0811.4% of flowCommon Stock, $0.01 par valueSEC:0001563545-26-000004:0
25 of 361 declarations
About AbbVie Inc.
AbbVie Inc. is a U.S. biopharmaceutical company listed on the NYSE under the ticker ABBV, with headquarters in North Chicago, Illinois, United States. The company was created in 2013 through the separation of Abbott Laboratories’ research-based pharmaceutical business, which gives AbbVie a relatively recent corporate history but a long operating lineage in branded pharmaceuticals. For French-speaking investors, AbbVie is best understood as a large-cap healthcare name with a defensive earnings profile, a strong dividend orientation, and meaningful exposure to high-value specialty medicines.
AbbVie’s business model is centered on global discovery, development, manufacturing, and commercialization of innovative medicines. The company reports a broad international footprint, serving patients in more than 170 countries and maintaining R&D and/or manufacturing operations in roughly 20 countries. Its strategy is built around a diversified portfolio across major therapeutic areas, primarily immunology, neuroscience, oncology, and aesthetics, with additional exposure to eye care in its reporting framework. This mix supports revenue diversification, although the company still depends heavily on a handful of blockbuster products.
Read moreShow less
The core revenue drivers include Skyrizi and Rinvoq in immunology, which have become the main growth engines as Humira continues its post-exclusivity decline. In neuroscience, AbbVie markets Botox Therapeutic, Vraylar, Ubrelvy, and Qulipta. In aesthetics, the portfolio includes Botox Cosmetic and Juvederm, while oncology is anchored by therapies such as Imbruvica, Venclexta, and Elahere. These brands give AbbVie a strong competitive position in several specialty categories with high barriers to entry, supported by a large commercial infrastructure and sustained R&D investment.
Competitive dynamics remain shaped by the Humira transition, but AbbVie has so far shown an ability to offset that pressure through strong uptake of Skyrizi and Rinvoq. Recent financial updates for 2024 and 2025 showed robust operating momentum, with newer immunology assets carrying the group and management reaffirming a strong medium-term growth outlook. Recent company announcements also point to continued pipeline expansion through acquisitions such as Nimble Therapeutics and Capstan Therapeutics, alongside positive clinical and regulatory progress in multiple programs, including tavapadon. For investors tracking U.S.-listed healthcare equities on the NYSE/NASDAQ, AbbVie remains a high-quality large-cap pharmaceutical name with a balance of cash generation, pipeline optionality, and transition risk from legacy products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
